ArticleFrontiers in medicine2023
Identification of novel pathways and immune profiles related to sarcopenia.
Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic value of sarcopenia in patients with nasopharyngeal carcinoma: a meta-analysis.Annals of medicine · 2025Pooled it
- Predictive role of preoperative sarcopenia for long-term survival in rectal cancer patients: A meta-analysis.PloS one · 2024Pooled it
- Computational analysis of hub genes associated with sarcopenia: integrative transcriptome insights from an Asian cohort.EXCLI journal · 2026Article
- Integrative bioinformatics analysis for identifying the mitochondrial-related gene associated with immune infiltration in sarcopenia.Medicine · 2025Article
- Neural Cues and Genomic Clues: NGS Insights into Neurogenic Sarcopenia and Muscle Atrophy.International journal of molecular sciences · 2025Review
- Analysis of lncRNAs and Their Regulatory Network in Skeletal Muscle Development of the Yangtze River Delta White Goat.Animals : an open access journal from MDPI · 2024Article
- Insights into the Therapeutic Potential of Active Ingredients ofInternational journal of molecular sciences · 2024Article
- Harnessing immunomodulation to combat sarcopenia: current insights and possible approaches.Immunity & ageing : I & A · 2024Review
- Myostatin and Activin A as Biomarkers of Sarcopenia in Inflammatory Bowel Disease Patients.Nutrients · 2024Article
- Characterizing the skeletal muscle immune microenvironment for sarcopenia: insights from transcriptome analysis and histological validation.Frontiers in immunology · 2024Article
- Zebrafish as an Emerging Model for Sarcopenia: Considerations, Current Insights, and Future Directions.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sarcopenia is a progressive deterioration of skeletal muscle mass strength and function. Methods: To uncover the underlying cellular and biological mechanisms, we studied the association between sarcopenia's three stages and the patient's ethnicity, identified a gene regulatory network based on motif enrichment in the upregulated gene set of sarcopenia, and compared the immunological landscape among sarcopenia stages. Results: We found that sarcopenia (S) was associated with GnRH, neurotrophin, Rap1, Ras, and p53 signaling pathways. Low muscle mass (LMM) patients showed activated pathways of VEGF signaling, B-cell receptor signaling, ErbB signaling, and T-cell receptor signaling. Low muscle mass and physical performance (LMM_LP) patients showed lower enrichment scores in B-cell receptor signaling, apoptosis, HIF-1 signaling, and the adaptive immune response pathways. Five common genes among DEGs and the elastic net regression model, Conclusion: This study provides new insight into sarcopenia's cellular and immunological prospects and evaluates the age and sarcopenia-related modifications of skeletal muscle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.